0

Global Antibody Drug Conjugates Market 2016-2020

  • Published: Mar 2016
  • Pages: 75
  • SKU: IRTNTR8911
Technavio

The 2022-2026 version of this report is just being published. Buy it now and get up to $1000 worth of free customization!

Get me the latest version! (includes COVID-19 impact)
Safe and Secure SSL Encrypted
  • 2500.00
  • USD

This market research study presents a detailed segmentation of the global antibody-drug conjugates market by mechanism of action (IgG1 antibodies and HER2 antibodies), by the technologies used (Seattle Genetics technology, ImmunoGen technology, and Immunomedics technology), and by geography (Americas, APAC, and EMEA). The key vendors in the market are F. Hoffmann-La Roche, Seattle Genetics, and Takeda Pharmaceuticals.

Outlook of the global antibody-drug conjugates (ADCs) market

According to the antibody drug conjugates industry insights, Technavio’s market research analysts have predicted the antibody-drug conjugates (ADCs) market to grow stupendously at a CAGR of more than 41% during the forecast period. Several products in the late-pipeline stage of clinical trials are expected to be launched over the predicted period which is expected to drive the growth prospects of this market. For instance, products like glembatumumab vedotin by Seattle Genetics, trastuzumab by Synthon Biopharmaceuticals are to be launched in the next five years. Moreover, some molecules are in Phase I/II, preclinical, and discovery stages. Altogether, there are several ADCs in the pipeline and their approval in the forecast period is expected to aid in the growth of this market.

In this industry research report, the analysts have estimated factors like the emergence of targeted and combination therapies will positively affect this market over the coming years. Targeted therapies have fewer adverse effects than conventional non-targeted therapies as targeted therapies exploit the surface markers of infected cells, which are absent or in lower amounts in normal cells. For instance, around 20% of all breast cancer cases are associated with the overexpression of HER2. Therefore, drugs that target TER2 receptors are administered as monotherapies or in combination for such cancers. Targeting multiple pathways with ADC in diseases such as cancer reduces the risk of developing treatment-resistant disorders, thereby aiding in the growth of this market in the predicted period.

Segmentation by mechanism of action and analysis of the ADCs market

  • IgG1 antibodies
  • HER2 antibodies

IgG is an antibody composed of four peptide chains and helps control the infection of tissues by binding to the pathogen such as virus, bacteria, and fungi. Moreover, these antibodies play an important role in intracellular antibody-mediated proteolysis and antibody-dependent cell mediated toxicity. IgG1 find extensive applications in immunotherapy and drug development, thereby propelling the growth prospects of the ADCs market. 

Geographical segmentation and analysis of the ADCs market

  • Americas
  • APAC
  • EMEA

Based on the antibody drug conjugates market outlook, the analysts have estimated that the Americas will dominate the global ADCs market until the end of 2020. This segment held the largest market share of more than 50% during 2015. The US was the largest revenue contributor in this region due to increasing incidences and prevalence of cancers.

Competitive landscape and key vendors

The global ADCs market is highly competitive due to the presence of only three major providers in the market. The entry of new vendors is likely to intensify the competition, both in terms of innovation and technology in the forecast period. The competitive environment is expected to increase in due to the product extensions, new products, and new applications of the products and services provided.  

Key vendors in this market are 

  • F. Hoffmann-La Roche
  • Seattle Genetics
  • Takeda Pharmaceuticals

Other prominent vendors analyzed in this market research report are AbbVie, AbGenomics, ADC Therapeutics, Agensys, ALMAC Group, Ambrx, Astellas Pharma, AstraZeneca, Bayer Healthcare, CARBOGEN AMCIS, Celldex Therapeutics, Daiichi Sankyo, Endo Pharmaceuticals, Esperance Pharmaceuticals, Formation Biologics, Genmab, GlaxoSmithKline, Immunogen, Kairos Therapeutics, MedImmune, Mersana Therapeutics, Novartis, Oxford Biotherapeutics, Pfizer, Stemcentrx, Synthon Biopharmaceuticals, and Zymeworks.

Key questions answered in the report include

  • What will the market size and the growth rate be in 2020?
  • What are the key factors driving the global ADCs market?
  • What are the key market trends impacting the growth of the global ADCs market?
  • What are the challenges to market growth?
  • Who are the key vendors in the global ADCs market?
  • What are the market opportunities and threats faced by the vendors in the global ADCs market?
  • Trending factors influencing the market shares of the Americas, APAC, and EMEA.
  • What are the key outcomes of the five forces analysis of global ADCs market?

Technavio also offers customization on reports based on specific client requirement.

Related reports:

 

Read More Read Less

Table of Contents

PART 01: Executive summary

  • Highlights

PART 02: Scope of  the report

  • Market overview
  • Top-vendor offerings
  • Assumptions

PART 03: Market research methodology

  • Research methodology
  • Economic indicators

PART 04: Introduction

  • Key market highlights

PART 05: Overview of ADCs

  • Antibodies
  • Evolution of mAb therapeutics
  • Conjugated mAbs
  • History
  • Key components in ADCs
  • Next-generation ADCs
  • Advantages
  • Challenges
  • Outsourcing of ADCs manufacturing
  • Emergence of ADCs
  • Current marketed ADCs
  • PART 06: Pipeline portfolio
  • Information on pipeline candidates

PART 07: Market landscape

  • Market overview
  • Market size and forecast
  • Five forces analysis

PART 08: Market segmentation  by MOA

  • IgG1 antibodies
  • HER2 antibodies

PART 09: Market segmentation by technologies used in ADCs

  • Seattle Genetics (SGEN) technology
  • ImmunoGen (IMGN) technology
  • Immunomedics (IMMU) technology

PART 10: Geographical segmentation

PART 11: Market drivers

  • Robust late-stage pipeline
  • Rising prevalence of cancers
  • Increase in demand for antibody conjugates
  • Reimbursement policies

PART 12: Impact of drivers

PART 13: Market challenges

  • High developmental costs
  • Stringent regulations
  • Risk of side effects

PART 14: Impact of drivers and challenges

PART 15: Market trends

  • Strategic alliances
  • Increased outsourcing of drug development
  • Emergence of targeted and combination therapies

PART 16: Vendor landscape

  • Competitive scenario
  • Key news
  • F. Hoffmann-La Roche
  • Seattle Genetics
  • Takeda Pharmaceuticals

PART 17: Appendix

  • List of abbreviations

PART 18: Explore Technavio

Research Framework

Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.

TechnavioINFORMATION SOURCES

Primary sources

  • Manufacturers and suppliers
  • Channel partners
  • Industry experts
  • Strategic decision makers

Secondary sources

  • Industry journals and periodicals
  • Government data
  • Financial reports of key industry players
  • Historical data
  • Press releases
Technavio

TechnavioDATA ANALYSIS

Data Synthesis

  • Collation of data
  • Estimation of key figures
  • Analysis of derived insights

Data Validation

  • Triangulation with data models
  • Reference against proprietary databases
  • Corroboration with industry experts
Technavio

TechnavioREPORT WRITING

Qualitative

  • Market drivers
  • Market challenges
  • Market trends
  • Five forces analysis

Quantitative

  • Market size and forecast
  • Market segmentation
  • Geographical insights
  • Competitive landscape
Interested in this report?
Get your FREE sample now!
Safe and Secure SSL Encrypted
Technavio

Single User:

2500 USD

Technavio Get the report (PDF) sent to your email within minutes.

Subscribe & Save

Get lifetime access to our
Technavio Insights

Want to customize this report?

This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time.

We offer $1000 worth of FREE customization at the time of purchase
Technavio
Enquire Before Buying
  1. Home
  2. Health Care
  3. Published Report
17,000 reports available | Plans starting from just 5,000 USD | Get FREE trial>>